Jieduquyuziyin Prescription Alleviates SLE Complicated by Atherosclerosis via Promoting Cholesterol Efflux and Suppressing TLR9/MyD88 Activation

The study demonstrates that the Jieduquyuziyin prescription (JP), a traditional Chinese medicine, effectively alleviates systemic lupus erythematosus (SLE) complicated by atherosclerosis in ApoE-/- mice. JP reduced hair loss, stabilized body weight, and alleviated kidney damage, while also decreasing urinary protein, autoantibodies, and inflammatory factors. It inhibited aortic plaque deposition, stimulated lipid metabolism, and increased the expression of genes regulating cholesterol efflux (ABCA1, ABCG1, SR-BI, PPAR-γ). Additionally, JP suppressed the TLR9/MyD88/NF-kB signaling pathway, reducing inflammation and foam cell formation in macrophages. These findings suggest JP's potential therapeutic role in treating SLE with atherosclerosis by promoting cholesterol efflux and inhibiting inflammatory pathways.